Navigation Links
Pulmonary Drug Delivery Systems: Technologies and Global Markets
Date:12/19/2011

NEW YORK, Dec. 19, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pulmonary Drug Delivery Systems: Technologies and Global Markets

http://www.reportlinker.com/p0715870/Pulmonary-Drug-Delivery-Systems-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

REPORT SCOPE

INTRODUCTION STUDY GOALS AND OBJECTIVES

This BCC market research report, Pulmonary Drug Delivery Systems: Technologies and Global Markets, provides a detailed overview and thorough analysis of the present and future global market for pulmonary drug delivery technologies. This report analyzes in detail the pulmonary drug delivery technologies that are available and currently used and their markets. This report includes products in this market and detailed analyses of the markets and competitive environments. It also analyzes current and future market prospects. The report provides a comprehensive review of emerging pulmonary drug delivery technologies, particularly with regard to inhaled drug delivery systems. The analysis reviews technological developments, product innovations, and recent strategic industry activities of major players across different product categories. It reviews their strengths and weaknesses, opportunities, and the threats facing various devices and drugs in this market space. The report also reviews developments already on the market, major issues involved in the research and development (R&D) of more effective devices for drug delivery to the lungs, and new products in development.

REASONS FOR DOING THE STUDY

Pulmonary drug delivery has emerged as a more relevant alternative for delivering drugs. Respiratory conditions such as asthma, chronic obstructive pulmonary, and emphysema disease are therapeutic areas of the pulmonary sector. However, recent technological advancements have applied the application of pulmonary devices to the treatment of nonrespiratory conditions such diabetes and migraines. Advancements in formulating technology are expected to push sales of dry powder inhalers, replacing metered-dose inhalers to a large extent. Pulmonary delivery of drugs for the treatment of respiratory diseases stems from the fact that topical drug deposition to the infected lung gives a fast therapeutic effect and reduces side effects associated with key drugs. There is a need to understand the trends in this market, currently available devices and their problems, and the latest developments for drug delivery to the lungs.

SCOPE AND FORMAT

The report reviews global markets for drug delivery technologies and new developments, and forecasts trends for use of current devices for drug delivery and for safety and toxicology through 2016. The report presents important devices, technologies, and the latest developments, market share by device and disease type, current products on the market, market share by company or product, and statistical information for types of respiratory diseases prevalent worldwide, with special emphasis on the U.S. market. The report also includes current issues and trends affecting the industry including costs, and factors influencing demand will be discussed. The report covers products in development, new technologies, trends, alliances, patents, and mergers. The report offers market data with respect to segments and geography. It also provides market trends with respect to drivers, restraints, and opportunities.

INTENDED AUDIENCE

This report is an exhaustive study of the worldwide drug delivery market, giving crucial statistics and analysis on existing technologies, the latest trends, market structure, market size, key drug segments, important trends in technology development, major opportunities, and market shares of key players and drugs. This report may prove crucial for drug development companies in drug delivery space, potential investors in the concerned sector. This report shows devices currently being used for drug delivery to the lungs, new developments, spending trends, and revenue prospects for these technologies. The report provides market data for 2010 to 2016 and also covers commercial prospects for pulmonary devices and current inhalers in use and their future.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news, and developments and access to paid databases. The base year of the report is 2010, with forecast data provided through 2016. Historical, base year, and forecast data are provided for each market segment of this report. The report provides a comprehensive review of emerging drug delivery technologies, particularly with regard to inhaled drug delivery systems. The new analysis reviews technological developments, product innovations/introductions, and recent strategic industry activities of major players across various product categories. Growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D, and current product growth.

Table of Contents CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE AND FORMAT 1

INTENDED AUDIENCE 2

METHODOLOGY 2

RELATED BCC STUDIES 2

ANALYST CREDENTIALS 3

BCC ON-LINE SERVICES 3

DISCLAIMER 3

CHAPTER TWO: SUMMARY 4

SUMMARY 4

SUMMARY (CONTINUED) 5

SUMMARY TABLE GLOBAL MARKET FOR PULMONARY DRUG

DELIVERY TECHNOLOGIES, THROUGH 2016 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL MARKET FOR PULMONARY DRUG

DELIVERY TECHNOLOGIES, 2010–2016 ($ MILLIONS) 6

CHAPTER THREE: OVERVIEW 7

TECHNOLOGY TRENDS 7

PULMONARY DRUG DELIVERY 8

PULMONARY CONDITIONS AND THERAPIES 8

RESPIRATORY SYSTEM 9

Respiratory System (Continued) 10

Lung 11

Particle Size, Toxicity and Drug Deposition 11

SYSTEMIC AND LOCAL THERAPY 12

Pulmonary Drug Delivery-Devices 13

Device Characteristics 13

Device Characteristics (Continued) 14

Device Characteristics (Continued) 15

Device Characteristics (Continued) 16

Device Characteristics (Continued) 17

Device Characteristics (Continued) 18

Pulmonary Drug Delivery – the Future 19

Inhaler Devices 19

TABLE 1 INHALER DEVICES AND CHARACTERISTICS 19

TABLE 2 DOSAGE FORMS-INHALERS 20

Available Products 20

TABLE 3 METERED DOSE INHALERS 20

Available Products (Continued) 21

TABLE 4 DRY POWDER INHALERS 22

INHALER-DRUG PROFILES 22

Aerosol Aztreonam (Cayston) 22

Dulera (mometasone furoate/formoterol fumarate

dihydrate) 23

Amikacin 24

SYSTEMIC PULMONARY DELIVERY 25

Development of Exubera 25

Lung Cancer Concerns 26

Aerogen and Dance Pharmaceuticals 27

Safety Concerns 27

Future 27

Insulin -Exubera 28

MannKind's –Afrezza 29

Summary 30

Key Players 30

Pulmonary Drug Delivery-In a New Light 30

ASTHMA AND COPD – MAJOR RESPIRATORY DISEASE

CONDITIONS 31

Asthma: Primary Respiratory Syndrome 31

Asthma: Primary Respiratory … (Continued) 32

Asthma and Obesity 33

TABLE 5 ASTHMA AND BIOMARKERS 34

Monitoring of Asthma 35

TABLE 6 INHALED STEROIDS (ASTHMA INHALERS) 36

TABLE 7 SYSTEMIC STEROIDS FOR ASTHMA TREATMENT 37

Delivery Methods 37

Delivery Methods (Continued) 38

Delivery Methods (Continued) 39

Chronic Obstructive Pulmonary Disease (COPD) 40

What is COPD? 40

COPD and Causative Factors 41

TABLE 8 COPD AND LUNG DAMAGE 42

COPD and … (Continued) 43

Diagnosis of COPD 44

COPD and Treatment 45

Methods of Drug Delivery 46

METHODS OF DRUG DELIVERY 47

Aerosols 47

TABLE 9 COPD DRUGS ON THE MARKET 48

Formulations 49

INHALATION MARKET 49

Asthma Prevalence and Statistics 49

COPD and Incidence 50

Disease and Epidemiology 51

TABLE 10 INHALED DRUGS AND MARKET OPPORTUNITIES:

CURRENT MARKET FOR INHALED DRUGS (% MARKET SHARE) 52

CHAPTER FOUR: PULMONARY DRUG DELIVERY SYSTEM 53

BENEFITS OF PULMONARY DRUG DELIVERY SYSTEMS 53

INHALER DEVICES 53

TABLE 11 INHALER DEVICES 54

Pulmonary Drug Delivery Technologies 54

Technology Descriptions 54

Wide Array of Applications 54

TABLE 12 DRUGS AND THERAPEUTIC AGENTS ADMINISTERED BY

INHALATION 55

Types of Inhalation Devices 55

Inhalers 55

Metered-dose Inhalers 56

MDIs-How Does It Work? 56

History 57

MDIs and Drug Delivery 57

Advantages and Challenges for MDIs 58

MDIs and Corticosteroids 58

TABLE 13 BRAND NAME METERED DOSE INHALERS

(CORTICOSTEROIDS) 59

Bronchodilators 59

TABLE 14 BRAND NAME METERED DOSE INHALERS

(BRONCHODILATORS) 59

Combination Inhalers 59

Nonsteroidal Inhalers 60

Problems with MDI Use and Spacers 60

Problems with …(Continued) 61

Propellants and MDI Development 62

TABLE 15 LIST OF METERED DOSE INHALERS AND INGREDIENTS 63

Fluticascone 63

Fluticasone and Salmeterol 64

Flunisolide 64

Beclomethasone 64

Transition to HFA propellants 65

Chlorofluorocarbons (CFCs) 65

TABLE 16 THE SEVEN CFC INHALERS 66

Analgesic Inhalers 66

Dry Powder Inhaler (DPI) 67

Dry Powder … (Continued) 68

TABLE 17 TYPES OF DPI DEVICES 69

Types of DPI Devices 69

TABLE 18 DPIS CURRENTLY ON THE MARKET 70

TABLE 18 (CONTINUED) 71

TABLE 19 DPI: ADVANTAGES VERSUS DISADVANTAGES 72

TABLE 20 TYPES OF DRY POWDER INHALERS (DPI) 72

DPIs for Children 72

Nebulizers 73

How Do They Work? 73

Use 74

TABLE 21 NEBULIZERS AND DRUGS 74

Use (Continued) 75

TABLE 22 NEBULIZERS: ADVANTAGES AND DISADVANTAGES 76

Ultrasonic Nebulizers 76

TABLE 23 VIBRATING MESH NEBULIZERS 77

Factors Influencing Clinical Effectiveness of Inhalation

Devices 78

CONCLUSIONS 79

CHAPTER FIVE: PULMONARY DRUG DELIVERY: DRUGS IN USE 80

CURRENT INHALATION DRUGS AND MARKET 80

AEROSOL AZTREONAM (CAYSTON) 80

DULERA (MOMETASONE FUROATE/FORMOTEROL

FUMARATE DIHYDRATE) 81

AMIKACIN 82

PULMONARY DELIVERY OF SYSTEMIC DRUGS 83

Antibiotics 83

Analgesics 83

Anti-emetics 83

TABLE 24 THERAPEUTIC AGENTS ADMINISTERED BY

INHALATION 84

Pulmonary Specific Vasodilators 84

Nicotine 85

Nebulizers for Pediatric Care 85

Vaccines 85

Obesity 85

Drugs and Inhalers: How do they Work? 85

TABLE 25 SHORT-ACTING BRONCHODILATOR INHALERS 86

TABLE 26 LONG-ACTING BRONCHODILATOR INHALERS 86

Steroid Inhalers 87

TABLE 27 INHALED STEROID MEDICATIONS 87

TABLE 28 COMBINATION INHALERS 87

Breath-Activated Inhalers 88

Nebulizers 88

Pulmonary Delivery 89

Controlled Release 89

Controlled Release (Continued) 90

Controlled Release (Continued) 91

Formulations 92

Lactose Carrier Systems 92

Liposomes 93

Liposomes (Continued) 94

PulmoSpheres 95

Biodegradable Polymers 96

CHAPTER SIX: GLOBAL MARKET FOR PULMONARY DRUG

DELIVERY TECHNOLOGIES 97

GLOBAL RESPIRATORY MARKET 97

DRUG DELIVERY MARKET 98

Drug Delivery Technologies and Market 98

GLOBAL PHARMACEUTICAL MARKET 99

TABLE 29 GLOBAL PHARMACEUTICAL SALES, THROUGH 2016 ($

BILLIONS) 100

FIGURE 1 GLOBAL PHARMACEUTICAL SALES, 2010–2016 ($

BILLIONS) 100

Pharmaceutical Growth Rates 101

A Shift to Generics as Patents Expire 101

Growth in New Drugs 101

Recent Mergers and Acquisitions (M&A Deals) 102

Emerging Markets 103

United States Pharmaceutical Industry 104

Top 20 Pharmaceutical Companies 105

TABLE 30 TOP 20 PHARMACEUTICAL COMPANIES IN 2011 ($

MILLIONS) 106

TABLE 30 (CONTINUED) 107

TABLE 31 TOP 20 PHARMACEUTICAL COMPANIES IN 2010 ($

MILLIONS) 107

TABLE 31 (CONTINUED) 108

TABLE 32 TWELVE LARGEST PHARMACEUTICAL COMPANIES IN

2010 ($ MILLIONS) 108

India and the Pharmaceutical Market 109

DRUG DELIVERY MARKET 109

Global Market 109

TABLE 33 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES

MARKET, THROUGH 2016 ($ MILLIONS) 110

FIGURE 2 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES

MARKET, 2010–2016 ($ MILLIONS) 111

TABLE 34 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET,

THROUGH 2016 ($ MILLIONS) 111

FIGURE 3 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET,

2010–2016 ($ MILLIONS) 112

Oral Drug Delivery 112

TABLE 35 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES

MARKET, THROUGH 2016 ($ MILLIONS) 113

FIGURE 4 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES

MARKET, 2010–2016 ($ MILLIONS) 113

Implantable and Injectable Drug Delivery 114

TABLE 36 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY

MARKET, THROUGH 2016 ($ MILLIONS) 114

FIGURE 5 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY

MARKET, 2010–2016 ($ MILLIONS) 115

Transdermal Drug Delivery 116

TABLE 37 GLOBAL TRANSDERMAL DRUG DELIVERY

TECHNOLOGIES MARKET, THROUGH 2016 ($ MILLIONS) 116

FIGURE 6 GLOBAL TRANSDERMAL DRUG DELIVERY

TECHNOLOGIES MARKET, 2010–2016 ($ MILLIONS) 117

Drug Delivery Market in the US 117

TABLE 38 US DRUG DELIVERY TECHNOLOGIES MARKET,

THROUGH 2015 ($ MILLIONS) 117

FIGURE 7 US DRUG DELIVERY TECHNOLOGIES MARKET, 2010–

2016 ($ MILLIONS) 118

Pulmonary Drug Delivery 118

TABLE 39 TYPES OF INHALER UNITS SOLD WORLDWIDE, 2007 (%) 119

TABLE 40 GLOBAL PULMONARY DELIVERY TECHNOLOGIES

MARKET, THROUGH 2016 ($ MILLIONS) 119

FIGURE 8 GLOBAL PULMONARY DELIVERY TECHNOLOGIES

MARKET, 2010–2016 ($ MILLIONS) 120

TABLE 41 PULMONARY DELIVERY TECHNOLOGIES MARKET IN

THE US AND EUROPE, THROUGH 2016 ($ MILLIONS) 120

FIGURE 9 PULMONARY DRUG DELIVERY TECHNOLOGIES

MARKET IN THE US AND EUROPE, 2010–2016 ($ MILLIONS) 121

PULMONARY DRUG DELIVERY SYSTEMS 122

Metered Dose Inhalers (MDIs) 122

Leading Inhalation Prescription Drugs across All

Segments 123

TABLE 42 MARKET FOR MDI TECHNOLOGIES, THROUGH 2016 ($

MILLIONS) 124

FIGURE 10 MARKET FOR MDI TECHNOLOGIES, 2010–2016 ($

MILLIONS) 125

Dry Powder Inhalation (DPI) 125

TABLE 43 MARKET FOR DPI TECHNOLOGIES, THROUGH 2016 ($

MILLIONS) 126

FIGURE 11 MARKET FOR DPI TECHNOLOGIES, 2010–2016 ($

MILLIONS) 126

The Attractiveness of Inhalers 127

Phase-out of CFC inhalers and Future Developments 127

Phase-out of CFC …(Continued) 128

Phase-out of CFC …(Continued) 129

TABLE 44 SALES OF INHALED STEROIDS AND AEROSOL BETA

AGONISTS JANUARY TO JUNE 2007 ($ MILLIONS/%) 130

Dry Powder Inhalation: A Promising Technology 130

Dry Powder Inhalers 131

TABLE 45 DPI DEVICES (BRAND NAME/MANUFACTURER) 131

Growth for DPIs 132

TABLE 46 GROWTH AREAS FOR INHALERS 132

TOP SELLING INHALED DRUGS 132

Fluticasone/Salmeterol 133

Fluticasone/Salmeterol (Continued) 134

TABLE 47 TOP SELLING INHALERS, 2010 ($ MILLIONS) 135

Tiotropium Bromide 135

Tiotropium Bromide (Continued) 136

Tiotropium Bromide (Continued) 137

Other Drugs 138

MAJOR PLAYERS 138

GlaxoSmithKline 138

TABLE 48 TOP SELLING DRUGS IN 2010 (MILLIONS) 138

Nebulizers: Displaying Promising Growth 139

TABLE 49 GLOBAL RESPIRATORY DEVICE MARKET, THROUGH

2016 ($ MILLIONS) 139

FIGURE 12 GLOBAL RESPIRATORY DEVICE MARKET, 2010–2016 ($

MILLIONS) 139

Nebulizers: Displaying …(Continued) 140

TABLE 50 US RESPIRATORY DEVICE MARKET, THROUGH 2016 ($

MILLIONS) 141

FIGURE 13 US RESPIRATORY DEVICES MARKET, 2010–2016 ($

MILLIONS) 142

TABLE 51 GLOBAL MARKET FOR NEBULIZERS, THROUGH 2016 ($

MILLIONS) 142

FIGURE 14 GLOBAL MARKET FOR NEBULIZERS, 2010–2016 ($

MILLIONS) 143

Nebulizers on the Market 143

GLOBAL TRENDS AND INHALER MARKET 144

Asia 144

Asia (Continued) 145

Asia (Continued) 146

CHAPTER SEVEN: GLOBAL MARKET TRENDS 147

GLOBAL MARKET TRENDS 147

REGULATORY CHANGES –PULMONARY DRUG DELIVERY

HURDLES 148

INCREASED RESEARCH AND DEVELOPMENT EFFORTS 148

AEROSOL DELIVERY MARKET 149

Distribution Channels 149

GROWTH AND NEW DEVELOPMENTS 150

Pulmonary Disease Drug Market 151

Market Trends in Asia 151

Market Segmentation 152

Patient Involvement 153

Pulmonary Insulin 154

Exubera 155

Afrezza 155

Inhaled Small Molecule Therapeutics 156

TABLE 52 APPROVED PULMONARY DRUGS IN RECENT YEARS 156

TABLE 52 (CONTINUED) 157

SELECTED PROFILES OF NEW DRUGS ON THE MARKET 157

Dulera 157

Dulera (Continued) 158

Arcapta (indacaterol maleate inhalation powder) 159

Daliresp 160

Daliresp (Continued) 161

CHAPTER EIGHT: KEY COMPANIES 162

KEY COMPANIES 162

3M 163

AKELA PHARMA INC (CANADA) 163

ALEXZA PHARMACEUTICALS 164

ALKERMES 164

ALPHARX INC 165

AOP ORPHAN PHARMACEUTICLS 165

APT PHARMACEUTICALS, INC 166

ARADIGM CORPORATION (USA) 166

ASTRAZENECA PLC (UK) 167

AXENTIS PHARMA 167

CONSORT MEDICAL PLC (UK) 168

DAIICHI SANKYO 168

DEY LP (USA) 169

GILEAD SCIENCES 169

GLAXOSMITHKLINE PLC (UK) 169

GRACEWAY PHARMACEUTICALS, LLC (USA) 170

HOVIONE 170

INSPIRE PHARMACEUTICALS, INC 171

MANNKIND 171

MAP PHARMACEUTICALS 172

MERCK & CO 173

MICRODOSE THERAPEUTX 173

MPEX PHARMACEUTICALS 173

NEKTAR THERAPEUTICS 174

NEXT SAFETY 175

NOVARTIS INTERNATIONAL AG 175

ORIEL THERAPEUTICS, INC 175

PEARL THERAPEUTICS 176

PHARMAXIS 176

PULMATRIX 177

RESPIRICS 177

SAVARA 178

SKYEPHARMA PLC (UK) 178

SUNOVION PHARMACEUTICALS INC 179

SYNAIRGEN RESEARCH LTD 179

TEVA NORTH AMERICA 180

THERAVANCE 180

UNITED THERAPEUTICS 181

VECTURA GROUP PLC (UK) 181

CHAPTER NINE: DEVELOPMENTS AND COLLABORATIONS 182

CURRENT AND FUTURE DEVELOPMENTS 182

BAYER SCHERING PHARMA AG, GERMANY 182

CIVITAS THERAPEUTICS 183

DR REDDY'S LABORATORIES 184

MANNKIND'S INHALED INSULIN DRUG AFREZZA 184

MannKind's Inhaled … (Continued) 185

PEARL THERAPEUTICS 186

PULMATRIX 187

RESPIRA THERAPEUTICS 187

SANDOZ 188

SUNPHARMA 189

TEVA 190

Teva (Continued) 191

THERAVANCE AND GLAXOSMITHKLINE 192

UNITED THERAPEUTICS CORPORATION 193

PRODUCTS IN CLINICAL DEVELOPMENT 194

FENTANYL TAIFUN 194

Fentanyl Taifun (Continued) 195

SPIRIVA RESPIMAT MIST INHALER 196

THERAVANCE PHASE III WITH RELOVAIR 197

Theravance Phase III with Relovair (Continued) 198

CHAPTER TEN: PATENT ANALYSIS 199

PATENT LANDSCAPE 199

REGULATORY ISSUES 200

NEW PATENT FILINGS 201

COMPETITIVE LANDSCAPE 202

TABLE 53 AREAS FOR DRUG DELIVERY IMPROVEMENTS 202

KEY PATENTS 202

Advair and Patent Issues 202

TABLE 54 PULMONARY DRUG DELIVERY TECHNOLOGIES AND

KEY PATENTS 203

Advair and Patent Issues (Continued) 204

Proventil HFA 205

REFERENCES 206

REFERENCES 206

REFERENCES (CONTINUED) 207

To order this report:Drug Delivery Technology Industry: Pulmonary Drug Delivery Systems: Technologies and Global Markets

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

 

 


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension
2. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
3. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
4. PRA Experts Pulmonary Function Textbook Reissued
5. The Pulmonary Hypertension Association and MedicAlert Foundation Form Alliance to Safeguard Patients
6. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
7. FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease
8. FREEDOM-M Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Meets Primary Endpoint
9. Reportlinker Adds Epidemiology: Major Abdominal Surgery - A key risk factor for deep vein thrombosis and pulmonary embolism
10. VIDA Diagnostics Launches Apollo Pulmonary Analysis Software for Major Lung Disease at American Thoracic Society Meeting
11. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
(Date:6/23/2016)... , June 23, 2016 ... "OTC Distribution in Europe 2016 Edition: The New Global Agenda ... OTC Distribution in Europe ... study that explores and tracks change. It identifies the driving ... environment for the consumer healthcare industry now and in the ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):